Home › Idiopathic Thrombocytopenic Purpura
Idiopathic Thrombocytopenic Purpura clinical trials recruiting in the U.S.
16 studies for Idiopathic Thrombocytopenic Purpura are recruiting participants at sites across the United States.
Cities with the most studies
- Los Angeles, CA7 studies
- Washington, DC7 studies
- Boston, MA7 studies
- The Bronx, NY5 studies
- Seattle, WA5 studies
- Greenville, NC5 studies
- Durham, NC5 studies
- Houston, TX4 studies
- Rochester, MN4 studies
- Philadelphia, PA4 studies
- Portland, OR4 studies
- Peoria, IL3 studies
- New Orleans, LA3 studies
- New Haven, CT3 studies
- Cedar Rapids, IA3 studies
- Cleveland, OH3 studies
- Kansas City, MO3 studies
By state
- Arizona3 studies
- Arkansas3 studies
- California11 studies
- Connecticut3 studies
- District of Columbia7 studies
- Florida3 studies
- Illinois5 studies
- Iowa3 studies
- Louisiana4 studies
- Massachusetts7 studies
- Michigan3 studies
- Minnesota5 studies
- Missouri3 studies
- New Jersey4 studies
- New York7 studies
- North Carolina7 studies
- Ohio3 studies
- Oregon4 studies
- Pennsylvania4 studies
- Texas5 studies
- Virginia4 studies
- Washington5 studies
Recently updated studies
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07007962A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07421167A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06721013A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06722235Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07104565A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06948318A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Oct 22, 2026 · NCT07059000Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT07549698Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06817395A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07786077A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 17, 2026 · NCT07700238Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 14, 2026 · NCT07095127OM336 in Autoimmune Cytopenias
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Sep 3, 2026 · NCT07083960Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
RecruitingPhase 1
Ages 18 to 85 · All sexes · Updated Jul 22, 2026 · NCT06371417A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 1, 2026 · NCT06544499Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Apr 15, 2026 · NCT04323748From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.